Quest Partners LLC Buys 4,348 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Quest Partners LLC boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 434,800.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,349 shares of the company’s stock after acquiring an additional 4,348 shares during the period. Quest Partners LLC’s holdings in Amphastar Pharmaceuticals were worth $174,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in AMPH. YHB Investment Advisors Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the first quarter valued at approximately $27,000. Principal Securities Inc. bought a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at $34,000. Innealta Capital LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $55,000. Quadrant Capital Group LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after acquiring an additional 223 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the sale, the director now directly owns 33,971 shares of the company’s stock, valued at $1,463,130.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Richard K. Prins sold 17,101 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the transaction, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William J. Peters sold 10,282 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,979 shares of company stock worth $1,671,307. 27.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AMPH shares. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Stock Up 3.4 %

NASDAQ AMPH opened at $48.09 on Monday. The stock’s 50 day simple moving average is $43.44 and its 200 day simple moving average is $42.60. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The firm has a market cap of $2.34 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 0.85 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The company had revenue of $182.39 million for the quarter, compared to analysts’ expectations of $171.29 million. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.